Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of May 21, 2026, RARE trades at $24.00 with a market cap of $2.38B and a P/E ratio of -3.82. RARE moved +4.14% today. Year to date, RARE is +1.13%; over the trailing twelve months it is -37.43%. Its 52-week range spans $18.29 to $58.00. Analyst consensus is strong buy with an average price target of $48.86. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded RARE stock?
Recent politician trading activity in RARE includes disclosures from Gilbert Cisneros and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
RARE Key Metrics
Key financial metrics for RARE
Metric
Value
Price
$24.00
Market Cap
$2.38B
P/E Ratio
-3.82
EPS
$-6.10
Dividend Yield
0.00%
52-Week High
$58.00
52-Week Low
$18.29
Volume
1
Avg Volume
0
Revenue (TTM)
$669.71M
Net Income
$-608.92M
Gross Margin
0.00%
Congressional Trades in RARE
Gilbert Cisneros purchase RARE on Feb 18, 2026 (amount: $15.00K).
Gilbert Cisneros purchase RARE on Jul 15, 2025 (amount: $15.00K).
Recent politician trading activity in RARE includes disclosures from Gilbert Cisneros and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in RARE?
Yes. Rallies tracks politician and congressional stock disclosures for RARE, including reported purchases, sales, dates, owners, and trade amounts when available.
Is RARE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RARE. It does not provide personalized investment advice.
